Read the latest from Baszucki Group and its partners.
A pilot study published today in Communications Medicine demonstrates the potential of a new approach to treating anorexia nervosa — a disorder for which effective treatments have been significantly limited.
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy’s ability to improve patients’ mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness.
April 27, 2026—You may think of the high-fat, low-carb eating plan as a faddish way to lose weight. But the keto diet is now being used to tackle conditions from severe depression to bipolar disorder and anorexia, with transformative results.
March 30, 2026—HHS Secretary Robert F. Kennedy Jr. recently said that ketogenic metabolic therapy can ‘cure’ schizophrenia and bipolar disorder. While clinical researchers don’t go nearly that far, they have found that the 100-year-old epilepsy treatment can lead to dramatic improvements in some psychiatric patients.